Kathleen Welsh-Bohmer
Affiliations: | Psychiatry & Behavioral Sciences | Duke Medical School, Durham, NC, United States |
Google:
"Kathleen Welsh-Bohmer"Mean distance: (not calculated yet)
Collaborators
Sign in to add collaborator| Alexandra S. Atkins | collaborator | ||
| Jeffrey N. Browndyke | collaborator | 2003- | Duke Medical School |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Zhou X, Zou H, Lutz MW, et al. (2024) Assessing tilavonemab efficacy in early Alzheimer's disease via longitudinal item response theory modeling. Alzheimer's & Dementia (New York, N. Y.). 10: e12471 |
| Reese M, Wong MK, Cheong V, et al. (2024) Cognitive and cerebrospinal fluid Alzheimer's disease-related biomarker trajectories in older surgical patients and matched nonsurgical controls. Anesthesiology |
| Watts A, Haneline S, Welsh-Bohmer KA, et al. (2023) TOMM40 '523 Genotype Distinguishes Patterns of Cognitive Improvement for Executive Function in APOEɛ3 Homozygotes. Journal of Alzheimer's Disease : Jad |
| Grazia A, Altomare D, Preis L, et al. (2022) Feasibility of a standard cognitive assessment in European academic memory clinics. Alzheimer's & Dementia : the Journal of the Alzheimer's Association |
| Atkins AS, Kraus MS, Welch M, et al. (2022) Remote self-administration of digital cognitive tests using the Brief Assessment of Cognition: Feasibility, reliability, and sensitivity to subjective cognitive decline. Frontiers in Psychiatry. 13: 910896 |
| Kimmel HJ, Levine DA, Whitney RT, et al. (2021) A Mixed-Methods Study of the Impact of Mild Cognitive Impairment Diagnosis on Patient and Care Partner Perception of Health Risks. Journal of Alzheimer's Disease : Jad |
| Shadyab AH, LaCroix AZ, Feldman HH, et al. (2021) Recruitment of a multi-site randomized controlled trial of aerobic exercise for older adults with amnestic mild cognitive impairment: The EXERT trial. Alzheimer's & Dementia : the Journal of the Alzheimer's Association |
| Burns DK, Alexander RC, Welsh-Bohmer KA, et al. (2021) Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Neurology. 20: 537-547 |
| Levine DA, Galecki AT, Plassman BL, et al. (2021) The Association Between Mild Cognitive Impairment Diagnosis and Patient Treatment Preferences: a Survey of Older Adults. Journal of General Internal Medicine |
| Smith PJ, Mabe SM, Sherwood A, et al. (2020) Metabolic and Neurocognitive Changes Following Lifestyle Modification: Examination of Biomarkers from the ENLIGHTEN Randomized Clinical Trial. Journal of Alzheimer's Disease : Jad |